Viyash Scientific
VIYASHNSE

Viyash Scientific

₹266.303.55 (1.35%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
253.50
Today’s high
272.40
52 week low
167.95
52 week high
298.00
Open price
265.50
Previous close
262.75
Live volume
37,37,226
Lower circuit
210.20
Upper circuit
315.30

Fundamentals

Market Cap
₹11,567Cr
ROE
7.07%
P/E Ratio(TTM)
43.32
EPS(TTM)
6.07
P/B Ratio
4.10
Dividend Yield
0.00%
Industry P/E
37.57
Book Value
64.08
Debt to Equity
0.17
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹955
+2.01%
Profit (Cr)
₹79.29
+19.45%
02505007501k
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+20%
3Y CAGR+34%
Profit growthValue
1Y (TTM)+115%
3Y CAGR+57%

About

SeQuent Scientific Limited stands as India's foremost animal health player, demonstrating an expanding global presence with state-of-the-art manufacturing capabilities across multiple continents. Its core vision is to establish itself as a premier integrated animal health company dedicated to delivering high-quality veterinary solutions around the world. The company's mission focuses on competitively delivering quality products while upholding strict standards of quality, governance, and compliance in all its operations. It offers an integrated portfolio that includes Active Pharmaceutical Ingredients (APIs) and Finished Drug Formulations (FDFs) to meet the industry's evolving needs. Through its animal health brand Alivira, the company is focused on advancing veterinary care by offering solutions that promote the well-being of animals. The company maintains a vast global reach with product registrations across numerous dosage forms, serving customers in over 90 countries.;
CEO/MD
Mr. Rajaram Narayanan
Founded in
1985
NSE symbol
VIYASH

Shareholding pattern

Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Shareholder details

Mutual Funds Invested (2)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
PfizerPFIZER
₹4,990.40
-27.20 (0.54%)
L
    H
    22,965.5931.245.46
    ₹857.55
    -7.25 (0.84%)
    L
      H
      21,436.9132.364.54
      ₹7,792.50
      -114.00 (1.44%)
      L
        H
        19,764.25116.5222.64
        ₹1,380.30
        +28.60 (2.12%)
        L
          H
          18,706.6728.14.79
          Livesquawk
          Viyash Scientific reported Q1 consolidated net profit of ₹659M, up from ₹318M YoY.
          Livesquawk
          Viyash Scientific's Alivira Animal Health acquires Bioforlife Italia for €16.98M. The deal expands Alivira's presence in the animal health sector.
          Livesquawk
          Viyash Scientific aims for $1B revenue and $250M EBITDA by 2032. Targets $150-200M from companion animals and 25%+ ROCE.
          Livesquawk
          Carlyle may sell up to 10% stake in Viyash Scientific, holding 61.3%. The sale could occur via a block secondary sale mechanism, per CNBC TV18.
          2026
          11
          Aug
          Quarterly Result
          Release date
          19
          May
          Quarterly & Annual Result
          Release date
          5
          Feb
          Quarterly Result
          Release date
          2025
          14
          Nov
          Quarterly Result
          Release date
          8
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks